Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022 at 02:49 am IST
Share
Heron Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 41.91 million compared to USD 52.41 million a year ago. Basic loss per share from continuing operations was USD 0.38 compared to USD 0.51 a year ago. Diluted loss per share from continuing operations was USD 0.38 compared to USD 0.51 a year ago.
For the nine months, net loss was USD 162.16 million compared to USD 166.04 million a year ago. Basic loss per share from continuing operations was USD 1.54 compared to USD 1.71 a year ago. Diluted loss per share from continuing operations was USD 1.54 compared to USD 1.71 a year ago.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.